

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS FO Box 1450 Alexandra, Virginia 22313-1450 www.repto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/749,631	12/31/2003	Heinz-Werner Kleemann	DEAV2002/0094 US CNT	8300	
5487 ANDREA Q. F	7590 09/22/2008 RYAN	EXAM	EXAMINER		
SANOFI-AVE	NTIS U.S. LLC	ANDERSON,	ANDERSON, REBECCA L		
1041 ROUTE : MAIL CODE:		ART UNIT	PAPER NUMBER		
BRIDGEWAT	BRIDGEWATER, NJ 08807				
			NOTIFICATION DATE	DELIVERY MODE	
			09/22/2008	ELECTRONIC	

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPatent.E-Filing@sanofi-aventis.com andrea.ryan@sanofi-aventis.com

## Advisory Action Before the Filing of an Appeal Brief

Application No.		Applicant(s)	
	10/749,631	KLEEMANN ET AL.	
	Examiner	Art Unit	
	REBECCA L. ANDERSON	1626	

		REBECCA L. ANDERSON	1626	
	The MAILING DATE of this communication appe	ars on the cover sheet with the	correspondence add	ress
THE REP	PLY FILED 18 August 2008 FAILS TO PLACE THIS AF	PPLICATION IN CONDITION FOR	R ALLOWANCE.	
app app for 0	reply was filed after a final rejection, but prior to or on lication, applicant must timely file one of the following lication in condition for allowance; (2) a Notice of Appe Continued Examination (RCE) in compliance with 37 C ods:	replies: (1) an amendment, affidat eal (with appeal fee) in compliance	vit, or other evidence, was with 37 CFR 41.31; or	hich places the (3) a Request
	The period for reply expires 4 months from the mailing date	of the final rejection.		
b) 🗖	The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire to Examiner Note: 10 box 1 is checked, check either box (a) or MONTHS OF THE FINAL REJECTION. See MPEP 706.07(	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailin b). ONLY CHECK BOX (b) WHEN TH	ng date of the final rejection	n.
Extensions have been under 37 C set forth in may reduce	s of time may be obtained under 37 CFR 1.136(a). The date filled is the date for purposes of determining the period of ext FFR 1.17(a) is calculated from; (1) the expiration date of the s (b) above, if checked. Any reply received by the Office later e any earned patent term adjustment. See 37 CFR 1.704(b). OF APPEAL	on which the petition under 37 CFR 1. ension and the corresponding amoun hortened statutory period for reply orig than three months after the mailing de	t of the fee. The appropria ginally set in the final Office	ate extension fee e action; or (2) as
2. ☐ The filing Noti	Notice of Appeal was filed on A brief in comp g the Notice of Appeal (37 CFR 41.37(a)), or any exter ice of Appeal has been filed, any reply must be filed wi	sion thereof (37 CFR 41.37(e)), t	o avoid dismissal of the	
AMENDN				
(a)	e proposed amendment(s) filed after a final rejection, but they raise new issues that would require further cor. They raise the issue of new matter (see NOTE below	nsideration and/or search (see NC		cause
(c)	They are not deemed to place the application in bett	ter form for appeal by materially re	educing or simplifying t	ne issues for
(d)[	appeal; and/or They present additional claims without canceling a converse NOTE: (See 37 CFR 1.116 and 41.33(a)).	corresponding number of finally re	jected claims.	
	e amendments are not in compliance with 37 CFR 1.12 plicant's reply has overcome the following rejection(s):		ompliant Amendment (I	PTOL-324).
	wly proposed or amended claim(s) would be all -allowable claim(s).	owable if submitted in a separate,	timely filed amendmen	nt canceling the
how The	purposes of appeal, the proposed amendment(s): a) [ the new or amended claims would be rejected is provestatus of the claim(s) is (or will be) as follows: Im(s) allowed:		ill be entered and an e	xplanation of
Clai Clai	in(s) objected to: im(s) rejected: im(s) withdrawn from consideration:			
	TT OR OTHER EVIDENCE			
bec	affidavit or other evidence filed after a final action, but ause applicant failed to provide a showing of good and not earlier presented. See 37 CFR 1.116(e).			
ente	eaffidavit or other evidence filed after the date of filing ered because the affidavit or other evidence failed to o wing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appe	al and/or appellant fail:	s to provide a
	e affidavit or other evidence is entered. An explanation TFOR RECONSIDERATION/OTHER	n of the status of the claims after e	entry is below or attach	ed.
	e request for reconsideration has been considered but se Continuation Sheet.	does NOT place the application i	in condition for allowan	ce because:
12. 🔲 No	ote the attached Information <i>Disclosure Statement</i> (s). (her:	PTO/SB/08) Paper No(s)		

/Rebecca L Anderson/ Primary Examiner, Art Unit 1626 Continuation of 11, does NOT place the application in condition for allowance because: While applicant instantly argues that Lang does not disclose that quinoly land isoquinolyl are substituted and refers, for example, to claim 1 and claim 5 to shart quinolyl and isoquinolyl are not substituted (see for example a comparison of embodiment G and J in the instant remarks), it is noted that in column 33 both the C2-6alkenyl and C3-10 cycloalkyl are considered unsubstituted or without substituted with the listed variables and the optional substitution is written the same manner as for the quinolyl, isoquinolyl and phenyl in column 36 (see page 14 of the remarks filed 17/16/2008 where applicants state that the C2-6alkenyl and C3-10 cycloalkyl are unsubstituted or substituted); it is noted that Applicants have also acknowledged that the quinolyl and isoquinolyl can be substituted, see page 14 of the remarks filed 16 January 2008 where applicant refers, for example to col 4, lines 23-27, etc.; and lastly it is noted that the further limiting embodiments, for example in claim 5, provide that the quinolyl and isoquinolyl can be substituted, for example in claim 1. Additionally, the claims still include withdrawn claims with would require further search and consideration. The claim set submitted on 18 August 2008 does not amend any claims. Therefore, as the remarks have not been persuasive the claim objection and rejection are maintained.